Has Seladelpar been included in the scope of medical insurance reimbursement? What is the current status?

As of now, Seladelpar (Seladelpar) has not been officially launched in China, so it has not been included in the scope of medical insurance reimbursement. The drug is currently undergoing clinical research and applying for marketing in the United States, Europe and other regions. In the United States, Siladepa has obtained orphan drug qualification certification from the FDA and is applying for a new drug marketing authorization (NDA). In Europe, Siladepa is also undergoing clinical trials and regulatory approval processes.

In China, Siladepa has not yet received clinical trial approval from the National Medical Products Administration (NMPA), nor has it been included in the National Medical Insurance List. This means that the drug cannot currently be legally sold or reimbursed in China. However, as international clinical data accumulates and regulatory agencies pay attention to the drug, there may be more opportunities for collaboration and introduction in the future.

For Chinese patients, Siladepa is still in the clinical research phase and has not yet become an available treatment option. At present, drugs for the treatment of primary biliary cholangitis (PBC) mainly include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA). These drugs have been approved in China and included in the scope of medical insurance reimbursement, providing patients with effective treatment options.

In short, Siladepa has not been marketed in China, nor has it been included in the scope of medical insurance reimbursement. Patients should pay attention to the latest international developments of this drug and discuss treatment options suitable for their own conditions with their doctors. At the same time, we look forward to the drug being approved in China in the future to provide patients with more treatment options.

Reference materials:https://www.fda.gov/drugs/